INOVIO PHARMACEUTICALS INC (INO)
US45773H4092 - Common Stock
INO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of INO is average, but there are quite some concerns on its profitability. INO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year INO has reported negative net income.
In the past year INO has reported a negative cash flow from operations.
In the past 5 years INO always reported negative net income.
INO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
INO's Return On Assets of -79.04% is on the low side compared to the rest of the industry. INO is outperformed by 71.06% of its industry peers.
INO's Return On Equity of -115.14% is in line compared to the rest of the industry. INO outperforms 42.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.04% | ||
| ROE | -115.14% | ||
| ROIC | N/A |
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.64%
ROE(5y)-772.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
INO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, INO has less shares outstanding
The debt/assets ratio for INO is higher compared to a year ago.
2.2 Solvency
INO has an Altman-Z score of -12.40. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.40, INO is doing worse than 79.97% of the companies in the same industry.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.4 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 3.60 indicates that INO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.60, INO is in line with its industry, outperforming 40.92% of the companies in the same industry.
INO has a Quick Ratio of 3.60. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
INO has a Quick ratio (3.60) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The earnings per share for INO have decreased strongly by -76.50% in the last year.
The Revenue for INO has decreased by -91.88% in the past year. This is quite bad
Measured over the past years, INO shows a very negative growth in Revenue. The Revenue has been decreasing by -51.33% on average per year.
EPS 1Y (TTM)-76.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q55.56%
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.33%
Revenue growth Q2Q-14.46%
3.2 Future
Based on estimates for the next years, INO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.94% on average per year.
The Revenue is expected to grow by 19.62% on average over the next years. This is quite good.
EPS Next Y35.62%
EPS Next 2Y20.2%
EPS Next 3Y26.42%
EPS Next 5Y15.94%
Revenue Next Year-43.07%
Revenue Next 2Y157.26%
Revenue Next 3Y429.22%
Revenue Next 5Y19.62%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INO's earnings are expected to grow with 26.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.2%
EPS Next 3Y26.42%
5. Dividend
5.1 Amount
No dividends for INO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INOVIO PHARMACEUTICALS INC
NASDAQ:INO (4/26/2024, 7:00:02 PM)
After market: 10.38 -0.19 (-1.8%)10.57
+0.45 (+4.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap247.02M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.04% | ||
| ROE | -115.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-76.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y-51.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y